Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year-on-Year [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY U.S. net sales reached $63 million in Q1 2026, representing a 62% increase from $39 million in Q1 2025 and a 15% increase from $55 million in Q4 2025. Medincell receives mid- to high-single-digit royalties on UZEDY net sales and is eligible for up to $105M in commercial milestone payments, subject to the achievement of annual sales thresholds. UZEDY is a 1-Month and 2-Month subcutaneous risperidone LAI (Long-Acting Injectable). It received U.S. FDA approval for schizophrenia in April 2023 and for Bipolar I Disorder in October 2025. Olanzapine LAI The New Drug Application (NDA) for once-monthly olanzapine LAI for the treatment of schizophrenia in adults was accepted by the U.S. FDA in February 2026, with a regulatory decision anticipated in Q4 2026. In Europe, acceptance of the Marketing Authorization Application (MAA) is expected in Q2 2026. Teva Q1'26 results p
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Earnings Snapshot: Teva Pharmaceutical Industries tops Q1 estimates; maintains 2026 business outlook [Seeking Alpha]Seeking Alpha
- Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year-on-YearBusiness Wire
- Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined ExecutionGlobeNewswire
- Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy [Yahoo! Finance]Yahoo! Finance
- Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth StrategyGlobeNewswire
TEVA
Earnings
- 4/29/26 - Beat
TEVA
Sec Filings
- 4/29/26 - Form 8-K
- 3/31/26 - Form DEFA14A
- 3/31/26 - Form ARS
- TEVA's page on the SEC website